Detalles de la búsqueda
1.
Lung cancer and family-centered concerns.
Support Care Cancer
; 28(2): 497-505, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31065838
2.
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.
J Clin Oncol
; 42(11): 1311-1321, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38207230
3.
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
J Thorac Oncol
; 18(6): 731-743, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36775193
4.
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.
J Thorac Oncol
; 18(11): 1524-1537, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37247843
5.
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
J Thorac Oncol
; 17(3): 399-410, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34740862
6.
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Clin Cancer Res
; 26(15): 4135-4142, 2020 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32332016
7.
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC.
JTO Clin Res Rep
; 1(4): 100074, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34589955
8.
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Clin Cancer Res
; 26(11): 2615-2625, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32034073
9.
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.
J Oncol Pract
; 15(9): e825-e834, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31386608
Resultados
1 -
9
de 9
1
Próxima >
>>